Martin Gunnarsson

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology

Claire Bridel, Wessel N. van Wieringen, Henrik Zetterberg et al. · JAMA Neurology · 2019 · 760 citations · Full text

Life Sciences, Neurology, Neuroscience +14

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Gustavo Luna, Peter Alping, Joachim Burman et al. · JAMA Neurology · 2019 · 509 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +10

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

Lenka Novakova, Henrik Zetterberg, Peter Sundström et al. · Neurology · 2017 · 428 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

Martin Gunnarsson, Clas Malmeström, Markus Axelsson et al. · Annals of Neurology · 2010 · 347 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14